<DOC>
	<DOCNO>NCT01300143</DOCNO>
	<brief_summary>Indication : Hepatocellular carcinoma , maximum size 9 cm , single multiple node whose total tumor mass technically irradiate , non-resectable , candidate percutaneous therapy recommend treatment via hyperselective transarterial chemoembolisation ( TACE ) .</brief_summary>
	<brief_title>Association Conformational High-dose Radiotherapy Hyperselective Transarterial Chemoembolization Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description>: Phase II control randomized trial , multicenter , compare benefit additive conformational radiotherapy therapy hyperselective chemoembolisation ( TACE ) treatment use three TACE treatment ( standard care ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Age ≥ 18 year age ECOG 01 life expectancy ≥ 6 month Histologically prove hepatocellular carcinoma proven accord radiological biochemical criterion ( EASLAASLD ) cirrhotic patient Maximum lesion size ≤ 9 cm Noneligible surgery percutaneous therapy Premature ChildPugh A B ( 7 point ChildPugh score ) AST ALT &lt; 7 x UNL Technical possibility conformational external radiotherapy Technical possibility TACE All tumor mass must able treated TACE Written consent sign patient Patients affiliate social security system Metastatic illness Minimal lesion size ≤ 5 mm Non control viral replication B History radiotherapy abdominal level Subjects capable procreate without efficient contraception pregnancy nurse female patient Contraindication TACE external conformational radiotherapy Any concomitant experimental treatment Contraindication Doxorubicin Patients unable respect enslave respiratory constraint use site Patients unable understand information follow protocol instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>